



**G.C.I.G.**

**FINAL**

**ENDOMETRIAL CANCER COMMITTEE**

**FRIDAY, NOVEMBER 3, 2017, 9:30AM – 11:00AM**

**VAN SWIETENSAAL, MEDICAL UNIVERSITY OF VIENNA**

**CHAIR: S.GREGGI CO-CHAIR: C.CREUTZBERG**

**HARMONIZATION LIAISONS: VERHOEVEN (OPS); TU/EMBLETON (STATS)**

***PLEASE SIGN ATTENDANCE FORMS***

**AGENDA**

**Welcome and Introductions and COI Disclosures (real or perceived)** S. Greggi

**Approval of report/minutes: October 2016 (posted on GCIG website)**

**Motion:** \_\_\_\_\_ **Seconded:** \_\_\_\_\_

**CLOSED/PUBLISHED STUDIES:** S. Greggi

(DCS:PORTEC3); NRG-GOG-ACRIN: 233/6671, 249, 258, 3007, 277, 275;

**ONGOING TRIALS:**

MITO: ECCo; DGOG:PORTEC4; STATEC; NSGO: FANDANGO, EN2, PALEO; BGOG: EN5-SIENDO; MANGO: AtTEnd; NRG-GOG: 238;

**ACTIVATING TRIALS:**

MITO-Retrospective multicentre study on advanced endometrial carcinoma S. Greggi

**NEW PROPOSALS/CONCEPTS:**

NRG-GOG 3021 D. Miller

**CHALLENGING DEBATE:**

**Lymph node assessment: a SLN new era?**

Background & audience vote with respect to the clinical behaviour S. Greggi

"Universal" SLN, is there any evidence for potential benefit?

PRO

A.Mariani

CONTRA

T.Mould

Molecular stratification: could it obviate any LN assessment?

C.Creutzberg

**ADJOURN**